For a patient with metastatic liver cancer who has completed nine cycles of FOLFOX and is experiencing fatigue and neuropathy, should oxaliplatin be discontinued and the continuous 5‑FU infusion switched to oral capecitabine while continuing lenvatinib at the current dose, and what specific lenvatinib dose, capecitabine schedule, tumor‑marker monitoring, and timing of next imaging are recommended?

Discontinue Oxaliplatin and Transition to Maintenance Therapy

After 9 cycles of FOLFOX with significant fatigue and neuropathy, oxaliplatin should be discontinued immediately and the patient transitioned to maintenance therapy with capecitabine plus lenvatinib. This approach preserves disease control while substantially reducing treatment toxicity and improving quality of life 1.

---

Rationale for Stopping Oxaliplatin

The NCCN guidelines explicitly state that discontinuation of oxaliplatin from FOLFOX should be strongly considered after 3 months of therapy, or sooner for unacceptable neurotoxicity 1. Your patient has completed 9 cycles (approximately 4.5 months) and is experiencing:

• Severe fatigue requiring most of the day in bed
• Peripheral neuropathy with tingling
• Inability to stand for more than 20 minutes
• Marked reduction in daily activities

The OPTIMOX1 study demonstrated that a "stop-and-go" approach using oxaliplatin-free intervals decreased neurotoxicity without affecting overall survival 1. The OPTIMOX2 trial showed that maintenance therapy with fluoropyrimidine continuation (without oxaliplatin) achieved a median duration of disease control of 13.1 months versus 9.2 months with complete chemotherapy-free intervals 1.

Critical point: The patient should not receive oxaliplatin again until near-total resolution of neuropathy occurs 1. Given the excellent Y-90 and systemic treatment response described, continuing oxaliplatin risks permanent neuropathy without clear additional benefit.

---

Recommended Maintenance Regimen

Switch from Infusional 5-FU to Oral Capecitabine

Replace the 46-hour 5-FU infusion with oral capecitabine 1. The NCCN guidelines confirm that FOLFOX and CAPEOX (capecitabine plus oxaliplatin) can be used interchangeably, with a phase III trial showing similar median PFS (8.0 vs 8.5 months) and non-inferiority 1.

Specific capecitabine dosing:

• Standard dose: 1,000 mg/m² orally twice daily on days 1-14 of each 21-day cycle
• Alternative: 850-1,000 mg/m² twice daily if concerned about toxicity given prior treatment burden
• Take within 30 minutes after meals (morning and evening)

Key toxicity monitoring for capecitabine:

• Hand-foot syndrome (palmar-plantar erythrodysesthesia) – most important dose-limiting toxicity
• Diarrhea – can be severe; requires aggressive management
• Nausea and vomiting
• Mucositis/stomatitis
• Myelosuppression (less common than with infusional 5-FU)

The elimination of the 46-hour pump will significantly improve quality of life and reduce treatment burden.

---

Lenvatinib Management

Continue Current Dose Initially

Do not increase lenvatinib immediately – this aligns with the provider's sensible "marathon not sprint" approach given the patient's current fatigue 2, 3.

Current lenvatinib dose verification needed:

• Lenvatinib capsules come in 4 mg and 10 mg strengths
• Standard HCC dosing: 12 mg daily (body weight ≥60 kg) or 8 mg daily (body weight <60 kg)
• "One capsule daily" from the transcript is ambiguous – the new oncologist must verify the exact milligram dose

Gradual escalation strategy (if appropriate after recovery):

1. Allow 4-6 weeks for fatigue improvement after oxaliplatin discontinuation
2. Assess tolerance to capecitabine maintenance
3. Consider dose escalation only if:
   • Performance status improves to ECOG 0-1
   • Fatigue substantially resolves
   • No prohibitive toxicity from capecitabine
4. Potential escalation: increase by 4 mg increments every 2-4 weeks as tolerated

Lenvatinib toxicity monitoring:

• Hypertension (most common) – requires aggressive management
• Proteinuria – check urinalysis regularly
• Diarrhea – may be additive with capecitabine
• Fatigue – already present
• Hand-foot syndrome – may be additive with capecitabine
• Hypothyroidism – check TSH every 4-6 weeks
• Hepatotoxicity – monitor LFTs closely given liver disease

---

Tumor Marker and Imaging Surveillance

Tumor Marker Monitoring

Verify which marker dropped from 122 to 26:

• The transcript mentions both "C99" and AFP – this must be clarified from actual lab reports
• If AFP: monitor every 4-6 weeks during maintenance therapy
• If CA 19-9: the provider stated it normalized; continue monitoring every 4-6 weeks
• Rising markers during maintenance should prompt imaging evaluation

Imaging Schedule

Recommended surveillance during maintenance therapy:

• CT chest/abdomen/pelvis every 8-12 weeks (every 2-3 months)
• Earlier imaging (6 weeks) if:
  • Tumor markers rise significantly
  • New symptoms develop
  • Clinical concern for progression

The excellent Y-90 response (loss of enhancement/vascularity in treated tumors) and systemic response (darkening of untreated liver lesion) suggest effective disease control. However, treated lesions can eventually recur, and systemic therapy must continue.

---

Laboratory Monitoring During Maintenance

Every 2 weeks for first 2 cycles, then every 4 weeks:

• Complete blood count with differential
• Comprehensive metabolic panel (including liver enzymes, bilirubin, creatinine)
• Tumor markers (AFP and/or CA 19-9)

Every 4-6 weeks:

• TSH (lenvatinib can cause hypothyroidism)
• Urinalysis with protein (lenvatinib nephrotoxicity)

As clinically indicated:

• Blood pressure monitoring (weekly initially with lenvatinib)
• Coagulation studies if on anticoagulation

---

Common Pitfalls to Avoid

1. Do not restart oxaliplatin without near-complete neuropathy resolution – the guidelines are explicit that patients should not receive subsequent oxaliplatin until near-total resolution 1

2. Do not assume "one capsule" lenvatinib dose – verify exact milligram dose before any changes

3. Do not increase lenvatinib while patient is severely fatigued – allow recovery from oxaliplatin toxicity first

4. Do not ignore hand-foot syndrome – this is the dose-limiting toxicity for both capecitabine and lenvatinib; aggressive management with dose reduction prevents treatment discontinuation

5. Do not interpret "excellent Y-90 response" as cure – microscopic disease likely remains; maintenance systemic therapy is essential

6. Do not delay capecitabine dose reduction for grade 2-3 toxicity – early intervention prevents severe complications

---

Expected Outcomes with Maintenance Strategy

Quality of life improvement timeline:

• 2-4 weeks: Neuropathy symptoms should begin stabilizing (may not improve immediately)
• 4-8 weeks: Fatigue should substantially improve after oxaliplatin clearance
• 8-12 weeks: Energy levels should approach pre-treatment baseline if no progression

Disease control expectations: Based on OPTIMOX2 data, maintenance fluoropyrimidine therapy (now capecitabine) should provide:

• Median duration of disease control: approximately 13 months 1
• This is significantly better than complete treatment breaks (9.2 months)

When to consider treatment intensification:

• Only if clear radiographic progression occurs
• Performance status must be adequate (ECOG 0-1)
• Consider second-line options rather than oxaliplatin re-challenge given neuropathy

---

Specific Capecitabine Dosing Algorithm

Starting dose calculation:

1. Calculate body surface area (BSA)
2. Standard dose: 1,000 mg/m² twice daily × 14 days, then 7-day rest
3. For a patient with BSA 1.7 m²: 1,700 mg twice daily
4. Round to nearest capsule strength (150 mg and 500 mg available)
5. Example: 1,500 mg (three 500 mg capsules) twice daily

Dose modifications for toxicity:

• Grade 2 hand-foot syndrome or diarrhea: hold until grade ≤1, resume at 75% dose
• Grade 3 toxicity: hold until grade ≤1, resume at 50% dose
• Grade 4 toxicity: discontinue permanently

Renal dose adjustment:

• CrCl 30-50 mL/min: reduce to 75% of standard dose
• CrCl <30 mL/min: contraindicated

---

Documentation for New Oncologist

Essential information to transfer:

1. Exact current regimen:

   • Oxaliplatin: 85 mg/m² every 2 weeks × 9 cycles (STOP)
   • 5-FU: 400 mg/m² bolus + 2,400 mg/m² 46-hour infusion (SWITCH to capecitabine)
   • Lenvatinib: [VERIFY exact mg dose] daily (CONTINUE)

2. Best response achieved:

   • Y-90 treated tumors: excellent response with loss of enhancement
   • Untreated liver lesion: responding (darker appearance)
   • Portal vein tumor: stable
   • Tumor marker: declined from 122 to 26 [VERIFY which marker]
   • CA 19-9: normalized

3. Current toxicities:

   • Grade 2-3 peripheral neuropathy (tingling, functional impairment)
   • Grade 2-3 fatigue (bedbound most of day)
   • Gastrointestinal symptoms (increased urgency with restaurant food)

4. Liver function:

   • AST, ALT: good per provider
   • Bilirubin: functioning well per provider
   • Child-Pugh score: appears to be A based on description

This maintenance strategy prioritizes both cancer control and quality of life, consistent with the provider's stated goal of treating cancer as a "marathon" rather than maximizing drug intensity at the expense of the patient's well-being.